Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Hi-Tech OTCs up slightly in fiscal 2013; Pharmstandard spins off OTC unit; Nu Skin raises estimates; infant formula makers respond to China inquiry; Pennsylvania joins NPLEx; and Everett alleges Acella infringes in prenatals.

You may also be interested in...



Rx-Only Pseudoephedrine Stalls As Meth Solution In Tennessee, Indiana

Tennessee’s meth lab seizures are up this year, but CHPA says that’s because more labs are uncovered through the state’s participation in the NPLEx stop-sale system. Rx-only bills have stalled in several states, including Indiana, where lawmakers passed a bill to cap PSE purchases at about 61 grams per year.

Dexcom Touts G7 As ‘The Most Accurate CGM’ As It Prepares For US Launch

The US FDA has granted authorization to Dexcom to market its G7 continuous glucose monitor, which the company will launch in the next couple of months.

Finance Watch: $1.32bn In New Biopharma VC Financings As Year-End Approaches

Private Company Edition: In recent weeks, 19 companies disclosed venture capital funding of $20m or more, including FogPharma with a $178m series D round and Apogee’s $169m launch. Also, Avalon BioVentures spun out of Avalon Ventures with a $135m fund.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel